By ASSOCIATED PRESS The nation’s largest cancer center is launching a massive “moonshot” effort against eight specific forms of the disease, similar to the all-out push for space exploration 50 years ago. The University of Texas MD Anderson Cancer Center in Houston expects to spend as much as $3 billion on the project over the…
By ASSOCIATED PRESS The nation’s largest cancer center is launching a massive “moonshot” effort against eight specific forms of the disease, similar to the all-out push for space exploration 50 years ago. The University of Texas MD Anderson Cancer Center in Houston expects to spend as much as $3 billion on the project over the…
By ANDREW POLLACK Ten of the world’s largest pharmaceutical companies said on Wednesday that they would cooperate on research aimed at accelerating drug development, starting with streamlining clinical trials. Pharmaceutical companies have collaborated before on areas considered not directly competitive, like finding variants in the human genome and biomarkers to predict disease and the effectiveness…
By ANDREW POLLACK Ten of the world’s largest pharmaceutical companies said on Wednesday that they would cooperate on research aimed at accelerating drug development, starting with streamlining clinical trials. Pharmaceutical companies have collaborated before on areas considered not directly competitive, like finding variants in the human genome and biomarkers to predict disease and the effectiveness…
By STEPHANIE BEASLEY Cancer research advocates and lawmakers say the sequestration’s effects on the National Institutes of Health and the National Cancer Institute could have a devastating impact on the development of new cancer treatments , with one stakeholder saying the mandatory across-the-board cuts could also impact FDA’s oncology drug review times — an area…
By STEPHANIE BEASLEY Cancer research advocates and lawmakers say the sequestration’s effects on the National Institutes of Health and the National Cancer Institute could have a devastating impact on the development of new cancer treatments , with one stakeholder saying the mandatory across-the-board cuts could also impact FDA’s oncology drug review times — an area…
A story was published in the September 5, 2012 Wall Street Journal, “Article Says Agency Let Risky Drugs Hit Market,” about a commentary in the Journal of the American Medical Association (JAMA) , which discussed the potential safety risks associated with three recently approved drugs, and questioned the time in which new drugs are approved. Dr. Sigal’s…
A story was published in the September 5, 2012 Wall Street Journal, “Article Says Agency Let Risky Drugs Hit Market,” about a commentary in the Journal of the American Medical Association (JAMA) , which discussed the potential safety risks associated with three recently approved drugs, and questioned the time in which new drugs are approved. Dr. Sigal’s…
By ANNA EDNEY A $6.4 billion accord for U.S. drug and medical-device reviews is set to unravel just three months after taking effect as lawmakers squabble over budget cutbacks. Drug and device reviews, which rely heavily on fees paid by companies, may slow or halt in January because the Food and Drug Administration must…
By ANNA EDNEY A $6.4 billion accord for U.S. drug and medical-device reviews is set to unravel just three months after taking effect as lawmakers squabble over budget cutbacks. Drug and device reviews, which rely heavily on fees paid by companies, may slow or halt in January because the Food and Drug Administration must…
